← Back to Search

Non-invasive Ventilation

Standard Therapy for Asthma

N/A
Waitlist Available
Led By Patrick T Wilson, MD
Research Sponsored by Columbia University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year
Awards & highlights

Study Summary

This study is evaluating whether a breathing machine may help reduce asthma symptoms in children.

Eligible Conditions
  • Asthma
  • Childhood Asthma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year
This trial's timeline: 3 weeks for screening, Varies for treatment, and one year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Feasibility of successfully enrolling, randomizing, and completing data collection in 30 participants within one year.
Secondary outcome measures
Difference in Duration of continuous beta-agonist therapy
Difference in Heart Rate
Difference in Oxygen Saturation
+5 more
Other outcome measures
Cumulative Number of Adverse Events

Side effects data

From 2012 Phase 4 trial • 44 Patients • NCT01129336
47%
Constipation
33%
Nausea
33%
Neutropenia
27%
Fatigue
27%
Dyspnoea
27%
Vomiting
27%
Diarrhoea
20%
Arthralgia
20%
Oedema peripheral
20%
Myalgia
20%
Neuropathy peripheral
13%
Urinary tract infection
13%
Cough
13%
Upper respiratory tract infection
13%
Bone pain
13%
Asthenia
13%
Mucosal inflammation
13%
Thrombocytopenia
13%
Abdominal pain
13%
Nasopharyngitis
13%
Hypokalaemia
13%
Insomnia
13%
Nasal congestion
13%
Night sweats
13%
Hot flush
7%
Rash
7%
Urine output decreased
7%
Postoperative wound infection
7%
Hypocalcaemia
7%
Radiation skin injury
7%
Tremor
7%
Sleep disorder
7%
Back pain
7%
Sinus headache
7%
Productive cough
7%
Abdominal pain upper
7%
Dysphagia
7%
Anaemia
7%
Vulvovaginal candidiasis
7%
Alopecia
7%
Drug hypersensitivity
7%
Palpitations
7%
Stomatitis
7%
Weight increased
7%
Haemoglobin decreased
7%
Dehydration
7%
Oedema mouth
7%
Rectal haemorrhage
7%
Hyponatraemia
7%
Coagulopathy
7%
Abdominal distension
7%
Leukopenia
7%
Generalised oedema
7%
Deafness
7%
Lip ulceration
7%
Erythema of eyelid
7%
Abdominal discomfort
7%
Chest pain
7%
Jaundice
7%
Acute sinusitis
7%
Cellulitis
7%
Hypoalbuminaemia
7%
Platelet count decreased
7%
Hypochloraemia
7%
Musculoskeletal pain
7%
Pain in jaw
7%
Dizziness
7%
Bladder irritation
7%
Muscular weakness
7%
Headache
7%
Pain in extremity
7%
Wheezing
7%
Joint swelling
7%
Dyspnoea paroxysmal nocturnal
7%
Musculoskeletal chest pain
7%
Dysphonia
7%
Dermatitis contact
7%
Orthopnoea
7%
Dysgeusia
7%
Depression
7%
Oropharyngeal pain
7%
Hyperhidrosis
7%
Palmar-plantar erythrodysaesthesia syndrome
7%
Plantar erythema
7%
Lymphoedema
7%
Skin exfoliation
7%
Hypertension
7%
Flushing
100%
80%
60%
40%
20%
0%
Study treatment Arm
Patients Without Bone Metastases
Patients With Bone Metastases

Trial Design

2Treatment groups
Experimental Treatment
Group I: Standard Therapy plus BPAPExperimental Treatment2 Interventions
Application of BPAP along with standard status asthmaticus therapy with continuous beta-agonist, steroids and oxygen as needed.
Group II: Standard Therapy (Control)Experimental Treatment1 Intervention
Standard status asthmaticus therapy with continuous beta-agonist, steroids and oxygen as needed.

Find a Location

Who is running the clinical trial?

Columbia UniversityLead Sponsor
1,431 Previous Clinical Trials
2,460,831 Total Patients Enrolled
20 Trials studying Asthma
5,119 Patients Enrolled for Asthma
Patrick T Wilson, MDPrincipal InvestigatorColumbia University
1 Previous Clinical Trials
126 Total Patients Enrolled
1 Trials studying Asthma
126 Patients Enrolled for Asthma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~0 spots leftby Apr 2025